Posts

Posted on

JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, Nov. 14, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with  cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper’s products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper’s business and/or financial prospects, as well as briquilimab’s clinical and/or commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 https://rosenlegal.com/submit-form/?case_id=44811or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jspr-deadline-jspr-investors-have-opportunity-to-lead-jasper-therapeutics-inc-securities-fraud-lawsuit-302616197.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Mantiqueira USA Announces Acquisition of Hickman’s Egg Ranch, Marking U.S. Expansion

GREELEY, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) — Mantiqueira USA (MTQ USA) today announced it has entered a binding agreement to acquire Hickman’s Egg Ranch, a leading egg producer based in the Mountain and West Coast regions and ranked among the top 20 egg companies in the United States. The acquisition marks a significant milestone in MTQ USA’s launch and its long-term strategy to build a strong, scalable presence in the U.S. egg market.

MTQ USA operates as a joint venture between the Pinto Family, founders of Mantiqueira, and JBS N.V. (NYSE: JBS), one of the world’s leading food companies. 

“Expanding into the United States has long been a vision for our family, and taking this step through the acquisition of Hickman’s makes this moment especially meaningful,” said Leandro Pinto, Founder of Mantiqueira. “Hickman’s is a respected leader with a legacy of quality and service. Combining their deep industry expertise with our global experience positions MTQ USA for long-term success.”

The transaction is expected to close by the end of the year, pending customary closing conditions. Murilo Scarpa Pinto serves as President of MTQ USA.

“Launching MTQ USA through this acquisition creates a strong foundation built on complementary strengths,” said Murilo Scarpa Pinto, President, MTQ USA. “Hickman’s heritage, quality, and customer relationships—paired with global experience, resources and scale—give us the ability to provide exceptional service and grow with purpose. We are committed to honoring Hickman’s legacy while driving new opportunities for our customers and team members.”

Wesley Batista Filho, JBS USA CEO, emphasized the strategic importance of this move in the U.S. protein landscape.

“This acquisition is an important milestone for JBS in the United States, expanding our presence into a new and complementary protein category,” said Wesley Batista Filho, CEO, JBS USA. “By partnering with the Pinto Family through MTQ USA, we are creating strong synergies that will enhance collaboration, improve efficiency, and accelerate innovation. Hickman’s brings decades of experience and credibility in the American egg industry, and together we see significant opportunity to deliver more value to customers across the country.”

The acquisition of Hickman’s represents MTQ USA’s formal entry into the U.S. market and reinforces the company’s commitment to collaboration, diversification, and meeting evolving customer needs.

“Our family has spent generations building a company rooted in excellence and integrity,” said Glenn Hickman, President & CEO, Hickman’s Egg Ranch. “We are confident that this transition will bring even greater opportunities to our customers, employees and partners.”

Stephens Inc. served as financial advisor and Faegre Drinker Biddle & Reath LLP served as legal counsel to Hickman’s Egg Ranch, Inc. for this transaction.

About MTQ USA

MTQ USA is a newly formed egg production and distribution company created through a joint venture between the Pinto Family—founders of South America’s largest egg producer and No. 10 egg company in the world, Mantiqueira—and JBS N.V., one of the world’s leading food companies. Headquartered in Greeley, Colo., MTQ USA leverages global expertise, operational scale, and deep industry knowledge to deliver high-quality egg products to customers nationwide. The company is committed to responsible operations, long-term growth, and building a best-in-class platform in the U.S. egg industry.

Media Contact:

Nikki Richardson
[email protected]

DISCLAIMER

We make statements about future events that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our Management and information to which the Company currently has access. Statements about future events include information about our current intentions, beliefs or expectations, as well as those of the members of the Company’s Board of Directors and Officers.

Disclaimers with respect to forward-looking statements and information also include information on possible or presumed operating results, as well as statements that are preceded, followed or that include the words “believe,” “may,” “will,” “continue,” “expects,” “predicts,” “intends,” “plans,” “estimates,” or similar expressions.

Forward-looking statements and information are not guarantees of performance. They involve risks, uncertainties and assumptions because they refer to future events, depending, therefore, on circumstances that may or may not occur. Future results and shareholder value creation may differ materially from those expressed or implied by the forward-looking statements. Many of the factors that will determine these results and values are beyond our ability to control or predict.



Posted on

Masimo Issues Statement on California Jury Verdict Finding Patent Infringement by Apple and Awarding Masimo $634 Million in Damages

Masimo Issues Statement on California Jury Verdict Finding Patent Infringement by Apple and Awarding Masimo $634 Million in Damages

IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today issued the following statement in response to the jury verdict announced in the U.S. District Court for the Central District of California, which confirmed the validity of Masimo Patent No. 10,433,776, found Apple infringed this patent, and awarded Masimo $634 million in damages:

“We are pleased by this outcome, and appreciate the time and attention given to our case by the court and the jury. This is a significant win in our ongoing efforts to protect our innovations and intellectual property, which is crucial to our ability to develop technology that benefits patients. We remain committed to defending our IP rights moving forward.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements – Masimo

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding the outcome of future studies evaluating the real world performance of Masimo SET; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “on-going,” “opportunity,” “plan,” “potential,” “predicts,” “forecast,” “project,” “seek,” “should,” “will,” or “would,” the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: the ability for clinical studies to recruit eligible participants; the ability for the investigator to collect meaningful data; the design of the clinical protocol; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Investor Contact:

Eli Kammerman

(949) 297-7077

[email protected]

Media Contact:

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Consumer Electronics Technology Professional Services Health Wearables/Mobile Technology Health Technology Medical Devices Hospitals Legal Telemedicine/Virtual Medicine Hardware

MEDIA:

Posted on

Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

PR Newswire


MILWAUKEE
, Nov. 14, 2025 /PRNewswire/ — The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Repare shareholders will receive an estimated $1.82 per share in cash at closing, based on the company’s current estimates. The final payment amount will be determined by Repare’s cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling them to portions of future proceeds from existing partnerships and potential asset dispositions. The CVRs provide varying percentages of net proceeds from partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, ranging from 90% to 75% depending on timing over a 10-year period.

Repare insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Repare by imposing a significant penalty if Repare accepts a competing bid. We are investigating the conduct of the Repare board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302616105.html

SOURCE Ademi LLP

Posted on

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, Nov. 14, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”) of the important December 29, 2025 lead plaintiff deadline.

So what: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to the G6 and G7 continuous glucose monitoring (“CGM”) systems that were unauthorized by the U.S. Food and Drug Administration (the “FDA”); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) accordingly, defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dxcm-investors-have-opportunity-to-lead-dexcom-inc-securities-fraud-lawsuit-302616094.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Public Service Company of New Mexico Declares Preferred Dividend

PR Newswire

ALBUQUERQUE, N.M., Nov. 14, 2025 /PRNewswire/ — The Board of Directors of Public Service Company of New Mexico, a subsidiary of TXNM Energy (NYSE: TXNM), declared the regular quarterly dividend of $1.145 per share on the 4.58 percent series of cumulative preferred stock. The preferred stock dividend is payable January 15, 2026, to shareholders of record at the close of business December 31, 2025.

Background:

TXNM Energy (NYSE: TXNM), an energy holding company based in Albuquerque, New Mexico, delivers energy to more than 800,000 homes and businesses across Texas and New Mexico through its regulated utilities, TNMP and PNM. For more information, visit the company’s website at www.TXNMEnergy.com.

CONTACTS:


Analysts


Media

Lisa Goodman

Corporate Communications

(505) 241-2160

(505) 241-2743

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/public-service-company-of-new-mexico-declares-preferred-dividend-302616160.html

SOURCE TXNM Energy, Inc.

Posted on

OceanPal Inc. Announces NASDAQ Ticker Change from “OP” to “SVRN”

PR Newswire


ATHENS, Greece and NEW YORK, Nov. 14, 2025 /PRNewswire/ — OceanPal Inc. (NASDAQ: OP) (“OceanPal” or the “Company”) today announced that it plans to change its stock ticker symbol from “OP” to “SVRN”.

Beginning Monday, November 17, 2025, shares of the Company’s common stock will trade on Nasdaq under the new ticker symbol “SVRN” and all trading activity, regulatory filings, and market-related information will be reported under the new symbol. The Company is not undertaking any other corporate action that affects the rights of outstanding common stock, and no action is required by shareholders in connection with the ticker symbol change. The Company’s common stock will continue to be listed on Nasdaq, and its CUSIP will remain unchanged.

About OceanPal Inc.

OceanPal Inc. is a global provider of shipping transportation services, specializing in the ownership and operation of dry bulk vessels and product tankers. OP is engaged in the seaborne transportation of bulk commodities, including iron ore, coal, and grain, as well as refined petroleum products. OP’s fleet is primarily employed on time charter trips with short to medium duration and spot charters, with a strategic focus on maximizing long-term shareholder value.

About SovereignAI

SovereignAI is a wholly owned subsidiary of OP formed to implement the company’s digital asset treasury strategy, and developer of confidential AI infrastructure offering a superior path to get exposure to the intersection of AI and blockchain in the public markets. SovereignAI will use NEAR Protocol’s purpose-built technology to establish private, user-owned agentic commerce. Funds generated by SovereignAI’s holistic treasury management strategy of NEAR tokens will be used to further the Company’s goal of building unique blockchain-native AI infrastructure.

To learn more about SovereignAI, please visit: https://www.svrn.net/

Media Contact: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/oceanpal-inc-announces-nasdaq-ticker-change-from-op-to-svrn-302616156.html

SOURCE OceanPal Inc.

Posted on

FCX INVESTOR ALERT: Freeport-McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead the Freeport-McMoRan Class Action Lawsuit

PR Newswire


SAN DIEGO
, Nov. 14, 2025 /PRNewswire/ —  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”), have until January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan class action lawsuit.  Captioned Reed v. Freeport-McMoRan Inc., No. 25-cv-04243 (D. Ariz.), the Freeport-McMoRan class action lawsuit charges Freeport-McMoRan and certain of Freeport-McMoRan’s top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Freeport-McMoRan class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-freeport-mcmoran-inc-class-action-lawsuit-fcx.html
 

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Freeport-McMoRan engages in the mining of mineral properties in North America, South America, and Indonesia.  Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Papua, Indonesia, in which the Indonesian government holds a commercial interest, according to the complaint.

The Freeport-McMoRan class action lawsuit alleges that throughout the Class Period defendants made false and/or misleading statement and/or failed to disclose that: (i) Freeport-McMoRan did not adequately ensure safety at the Grasberg Block Cave mine in Indonesia; (ii) the lack of proper safety precautions constituted a heightened risk that could foreseeably lead to the death of Freeport-McMoRan’s workers; and (iii) this constituted an undisclosed heightened risk of regulatory, litigation, and reputational risk.

The Freeport-McMoRan class action lawsuit further alleges that on September 9, 2025, Freeport-McMoRan disclosed that “a large flow of wet material from a production drawpoint occurred at one of five production blocks in the Grasberg Block Cave underground mine,” which “blocked access to certain areas within the mine, restricting evacuation routes for seven team members.”  Freeport-McMoRan further allegedly disclosed that “[m]ining operations in the Grasberg minerals district have been temporarily suspended to prioritize the safe evacuation of the seven contractor workers.”  On this news, the price of Freeport-McMoRan stock fell nearly 6%, according to the complaint.

Then, on September 24, 2025, the complaint further alleges that Freeport-McMoRan revealed that “two team members . . . were regrettably fatally injured in the September 8th incident,” “[e]xtensive efforts are ongoing in the search for five [PT  Freeport Indonesia (“PTFI”)] team members who remain missing,” and “mining operations in the Grasberg minerals district have been temporarily suspended since September 8th.”  Freeport-McMoRan allegedly further disclosed that “PTFI production in 2026 could potentially be approximately 35% lower than pre-incident estimates.”  On this news, the price of Freeport-McMoRan stock fell nearly 17%, according to the complaint.

Finally, on September 25, 2025, the Freeport-McMoRan class action lawsuit alleges that Bloomberg published an article entitled “Freeport Mine Setback Risks Fraying Relations With Indonesia,” which stated, in pertinent part, that “[a] halt in production at the giant Grasberg copper mine in Indonesia looks set to strain the fractious relationship between Freeport-McMoRan Inc. and its host nation, at a time when the Jakarta government was already looking to take greater control.”  The complaint alleges that on this news, the price of Freeport-McMoRan stock fell more than 6%.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Freeport-McMoRan publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Freeport-McMoRan class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Freeport-McMoRan investor class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Freeport-McMoRan shareholder class action lawsuit.  An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Freeport-McMoRan class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:
               Robbins Geller Rudman & Dowd LLP
               J.C. Sanchez, Jennifer N. Caringal
               655 W. Broadway, Suite 1900, San Diego, CA 92101
               800-449-4900
              [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fcx-investor-alert-freeport-mcmoran-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-freeport-mcmoran-class-action-lawsuit-302616127.html

SOURCE Robbins Geller Rudman & Dowd LLP

Posted on

LRN LAWSUIT ALERT: Levi & Korsinsky Notifies Stride, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Stride investors who were adversely affected by alleged securities fraud between October 22, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form-3?prid=177507&wire=3

LRN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that Stride was (1) inflating enrollment numbers by retaining “ghost students”; (2) cutting staffing costs by assigning teachers’ caseloads far beyond the required statutory limits; (3) ignoring compliance requirements, including background checks and licensure laws for its employees, and ignoring federally mandated special education services to students; (4) suppressing whistleblowers who documented financial directives from Stride’s leadership to delay hiring and deny services to preserve profit margins; and (5) losing existing and potential enrollments.

WHAT’S NEXT? If you suffered a loss in Stride during the relevant time frame, you have until January 12, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com



Posted on

Genius Group files Federal Securities Class Action Lawsuit against Citadel Securities and Virtu Financial for Alleged Market Manipulation.

SINGAPORE, Nov. 14, 2025 (GLOBE NEWSWIRE) —
Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced it has filed a Class Action Complaint in the United States District Court for the Southern District of New York alleging that Citadel Securities LLC, and Virtu Americas LLC (the “Defendants”) engaged in a long-running market manipulation scheme that includes spoofing and naked short selling of the Company’s shares and related acts in violation of Section 10(b), Sections 9(a)(2) and 9(e) and Section 20(a) of the Securities Exchange Act of 1934.

The Company believes the lawsuit sets a number of precedents with regards to the protection of shareholder interests and the Company. As such, the Company is taking action to recover damages caused due to alleged market manipulation:


  • This lawsuit is a


    Class Action Complaint


    filed on behalf of the Company and ALL of its investors who sold Genius Group stock at artificially deflated prices as a result of Defendants’ alleged abuses.

  • Pursuing a class action will help the Company facilitate a recovery not just for Genius Group’s losses, but for all its harmed shareholders as well.

  • The Company will ask the Court to appoint it “lead plaintiff” in the class action, so that the Company can effectively manage the litigation and diligently work to protect its shareholders’ interests.

The class action complaint filed today that Defendants engaged in longstanding and widespread manipulative trading scheme centered on repeatedly “spoofing” Genius Group stock. “Spoofing” is a manipulative and illegal trading practice that involves submitting and then cancelling buy or sell orders without any genuine intent to execute them. The purpose of these “baiting orders” is to mislead other market participants about the level of supply and/or demand for a security, or about the degree of price volatility associated with a security, and thereby influence market prices for that security.

The complaint alleges that for a period of at least three years – between April 12, 2022 and May 30, 2025 (the “Class Period”) – Defendants repeatedly entered thousands of spoofing trades designed to create the false impression that there was both excess supply and excess volatility in Genius stock. The Company has confirmed that the lawsuit seeks at least the previously reported no less than $250 million in damages.

These manipulative orders were calculated to (and successfully did) deceive or induce other investors to sell their holdings at artificially deflated prices. In particular, the complaint alleges:

  • On 98%of all trading days during the Class Period, Defendants repeatedly entered spoofing trades designed to manipulate the price of Genius stock. Defendants entered dozens – sometimes thousands – of such trades on a given trading day, canceling them within milliseconds of placement.
  • Defendants repeatedly built massive short positions through off-exchange trading over a few trading days, and then bombarded the market with spoofing trades (baiting orders canceled within100 milliseconds of placement) causing significant declines in the price of Genius Group stock.

  • Less than a minute
     after these baiting orders were placed, Defendants sold significant volumes of Genius stock short through off-exchange trading.
  • Defendants also engaged in significant naked short-selling, i.e., improper short sales that are unsupported by existing market inventory. Indeed, major declines in Genius Group stock were also accompanied by large spikes in evidence of such activity.

In filing this class action, Genius Group is demonstrating its commitment to its shareholders and the Company intends to work diligently to protect their interests.

Roger James Hamilton, CEO of Genius Group, said “We have been consistent in calling for fair markets and taking actions to protect our shareholders. The filing of this lawsuit is an important milestone for the company in what has been a long, multi-year fight to protect the company and its shareholders and expose unfair and illegal practices that our investors have dealt with.”

“Even today, multiple brokers have taken away the buy button on Genius shares while leaving the sell button, making it hard to buy but easy to sell our stock without providing adequate explanation as to why they are choosing to target our company. We give notice to any and all bad actors seeking to profit at the expense of our shareholders that we will continue to take forceful, proactive action to defend our company.”

The Company and its legal team will continue to provide updates to its shareholders on this case as appropriate. The Company also reminds shareholders of the record date of November 28, 2025 to transfer shares via the Direct Registration System (DRS) to book entry with the Company’s transfer agent, VStock in order to benefit from the Bitcoin Loyalty Payment program, designed to reduce the number of Company shares available to short sellers. Full details of the program can be found here.

About Genius Group

Genius Group (NYSE: GNS) is a Bitcoin-first business delivering AI powered, education and acceleration solutions for the future of work. Genius Group serves 6 million users in over 100 countries through its Genius City model and online digital marketplace of AI training, AI tools and AI talent. It provides personalized, entrepreneurial AI pathways combining human talent with AI skills and AI solutions at the individual, enterprise and government level. To learn more, please visit https://www.geniusgroup.ai/

Forward-Looking Statements 

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will”, “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 20-F, as may be supplemented or amended by the Company’s Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contacts

For enquiries, contact [email protected]